Google

Archive for the ‘Immune System / Vaccines’ Category

Medicago Receives Contribution From NRC-IRAP For Seasonal Flu Vaccine Program

Tuesday, July 8th, 2008

Medicago Inc. (TSX VENTURE:MDG) announced it has been awarded a non-refundable contribution of up to $279,700 from Canada's National Research Council Industrial Research Assistance Program ("NRC-IRAP") to support the development of the Company's seasonal influenza Virus-Like Particles (VLP) vaccine program. Medicago is developing a seasonal vaccine based on its ...

A New Study Shows DispersinBTM Helps Our Body’s Immune Cells To Kill Bacteria

Monday, July 7th, 2008

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms, is pleased to announce a research publication on its DispersinBTM technology. The manuscript appeared in the recent online edition of Microbial Pathogenesis (2008), doi: 10/1016/j.micpath.2008.05.007. The publication, entitled "Both ...

GiveVaccines.org Creates Quiz Web Site To Donate Life-Saving Vaccines To Impoverished Children Around The World Through The GAVI Alliance

Monday, July 7th, 2008

Free Vaccine Inc., a non-profit organization dedicated to raising awareness about vaccine-preventable diseases and empowering individuals to be a part of the solution, has launched GiveVaccines.org. The site features a fast-paced vocabulary quiz focusing on word roots, English words and medical terminology. For every correct answer, GiveVaccines.org will donate ...

Hepatitis C Vaccine Delivered By Inovio Biomedical’s Electroporation System Shows Increased T-Cell Responses And Reduced Viral Loads, Study

Monday, July 7th, 2008

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported additional interim results from its ongoing phase I/II clinical study of its ChronVac-C® therapeutic DNA vaccine, which is delivered using Inovio's electroporation-based DNA delivery system. ...

UK Armed Forces In Iraq: Multiple Vaccines Not Responsible For Health Problems

Friday, July 4th, 2008

Servicepersonnel deployed to Iraq have not suffered ill health due to multiplevaccinations, according to a study released on July 1, 2008 in BMJ.Debaterelated to the impact that multiple vaccinations may have had on thehealth of veterans of the Gulf War will only be fueled by this newinformation. Before deployment to ...

Finding That Could Shed Light On Golden Staph, Candida And Allergies

Wednesday, July 2nd, 2008

Recent scientific findings explain why patients with a rare immunodeficiency disorder are unusually susceptible to certain common infections. By revealing the exact molecular mechanisms involved, they also give us clues as to why some 'healthy' people are more prone to these infections than others, and suggest potential treatments. People ...

Experts Urge Expanding Influenza Vaccination Season To Increase Immunization Rates, Protect More Americans

Tuesday, July 1st, 2008

Health care professionals should increase influenza immunization rates by implementing key, practice-proven interventions and offering vaccine at every opportunity throughout the entire influenza season, conclude leading influenza experts in a July 2008 supplement to The American Journal of Medicine. The experts assert that the medical community is not taking ...

New Route For Combating Viruses

Friday, June 27th, 2008

A unique technique for analyzing the function of microRNAs developed by a Hebrew University of Jerusalem doctoral student has led to the discovery of a new mechanism by which viruses evade the human immune system. This discovery has important implications for human intervention in the battle between viruses and humans.For ...

Start Of Phase 2a Clinical Study Of Angiotensin Therapeutic Vaccine In Hypertension

Thursday, June 26th, 2008

Protherics PLC "Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that the first patient has been enrolled in a phase 2a study of its Angiotensin Therapeutic Vaccine (ATV) for the treatment of hypertension.Hypertension is a major risk factor for serious and common ...

Sanofi Pasteur Inaugurates High Tech Vaccine Production Facility To Respond To Soaring Demand Worldwide

Thursday, June 26th, 2008

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide. This new 100 million euros facility located in Val de Reuil (North West of France) incorporates ...

Take Care Health Systems Offers Shingles Vaccine Nationwide

Tuesday, June 24th, 2008

Take Care Health Systems, one of the largest managers of convenient care clinics and a wholly-owned subsidiary of Walgreens (NYSE, NASDAQ: WAG), is now administering the shingles vaccine at all 177 Take Care Health Clinics located at Walgreens drugstores in 19 markets throughout 14 states. By administering the shingles vaccine ...

Exploring The Evolution Of Vertebrate Innate Immunity

Friday, June 20th, 2008

The immune system of vertebrate animals consists of two components: the innate immune response, a constitutive system ready to respond to a pathogen, and the adaptive immune response, a system of immunological memory that responds to previously encountered pathogens. In a study led by Dr. Anlong Xu of Sun Yat-sen ...

World’s Top Vaccine Scientists To Discuss The Latest Research

Friday, June 20th, 2008

Vaccines are critical tools in the fight to prevent high-burden infectious diseases in all age groups living in both industrialized and developing countries. Vaccine and public health experts will gather in Paris to review the promise of and challenges related to today's vaccine research, what new products are expected and ...

Novartis Vaccines And Diagnostics S.r.l. Withdraws Its Marketing Authorisation Application For The Pre-pandemic Vaccine Aflunov, Europe

Tuesday, June 17th, 2008

The European Medicines Agency (EMEA) has been formally notified by Novartis Vaccines and Diagnostics S.r.l. of its decision to withdraw the application for a centralised marketing authorisation for the pre-pandemic vaccine Aflunov (A/VietNam/1194/2004 (H5N1) virus surface inactivated antigen). Aflunov was expected to be used for active pre-pandemic immunization against ...

News From The Journal Of Clinical Investigation, June 12, 2008

Saturday, June 14th, 2008

New target to enhance anticancer drug sensitivity found in translationThe development of resistance to anticancer chemotherapeutic agents remains a large problem. In some cases, such resistance is associated with altered control of a cellular process known as translation, which is central to the generation of proteins. New data, generated by ...